AstraZeneca Invests $135M in Swedish Biologics Manufacturing Expansion

Investment Amount:
AstraZeneca is investing $135 million (SEK 1.5 billion) to expand its biologics manufacturing facility in Sweden.

Expansion Purpose:
The expansion aims to double the size of the facility due to increased demand for AstraZeneca's pre-filled syringe drug products.

Location:
The expansion is taking place at AstraZeneca's Sweden Biomanufacturing Center in Södertälje.

Demand Increase:
The investment is driven by a significant increase in demand for AstraZeneca's biologic drugs, particularly those delivered via pre-filled syringes.

Capacity Boost:
The expansion will enhance AstraZeneca's biologics manufacturing capacity, supporting the production of more pre-filled syringe drug products.